"New York State's Office of Cannabis Management (OCM) announced Thursday that it will lead a new clinical study on the effects of CBD and THC on patients living with inflammatory bowel disease (IBD). The observational study represents a first-of-its-kind effort by a state cannabis regulatory agency to advance medicinal cannabis research through designing and launching a medical study. OCM's Director of Scientific Programs & Research, Dr. Nakesha Abel, who will also serve as the study's lead investigator, said that to fully understand the medical benefits of cannabis, the industry needs to invest more in research."
"Research like this helps move the conversation about cannabis from anecdotal experiences to measurable data-driven patient outcomes, said Abel. The costs of IBD to New Yorkers Close to 3 million people in the United States are impacted by IBD with varying levels of severity, and the number of people impacted, along with treatment-related costs, continues to rise, according to the Mayo Clinic."
"Study participants will take 10-35 mg of CBD and THC orally daily to track how cannabis impacts the symptoms of IBD conditions, such as Crohn's disease and ulcerative colitis. These diseases cause inflammation and damage along a patient's intestinal tract, often leading to painful symptoms ranging from cramping, diarrhea, and sores to potentially life-threatening conditions such as bleeding, tearing, or intestinal blockages, according to the Centers for Disease Control (CDC)."
"Chief Medical Officer at OCM, Dr. Junella Chin, said that at times, IBD symptoms can become severe enough to disrupt patients' ability to function normally. Patients living with gastrointestinal conditions often face daily challenges that can significantly impact their quality of life, said Chin. Advancing comprehensive cannabis research is essential to expanding treatment options, underpinning support for patient care and strengthening our understanding of how cannabis co"
New York State’s Office of Cannabis Management will lead an observational clinical study on the effects of CBD and THC for patients living with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. The study is designed and launched by a state cannabis regulatory agency to advance medicinal cannabis research. Participants will take 10–35 mg of CBD and THC orally each day to track changes in IBD symptoms. IBD involves inflammation and damage to the intestinal tract, which can cause cramping, diarrhea, sores, bleeding, tearing, or intestinal blockages. The study aims to move cannabis understanding from anecdotal reports toward data-driven outcomes and to support expanded treatment options and patient care.
Read at www.amny.com
Unable to calculate read time
Collection
[
|
...
]